Goodpasture syndrome natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 16: Line 16:


== Prognosis ==
== Prognosis ==
* Prognosis is generally good for patients with Goodpasture syndrome who receive treatment.
* The 5 survival rate of patients with Goodpasture syndrome who receive treatment is approximately 80%.
* Recent advances in pharmacotherapy and use of immunosuppressive and plasmapheresis have further improved the outcome of patients with Goodpasture syndrome.
In the past the prognosis of Goodpasture syndrome was fatal.<ref name="pmid12597309">{{cite journal| author=Shah MK, Hugghins SY| title=Characteristics and outcomes of patients with Goodpasture's syndrome. | journal=South Med J | year= 2002 | volume= 95 | issue= 12 | pages= 1411-8 | pmid=12597309 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12597309  }}</ref> Today, the prognosis of Goodpasture syndrome is heavily dependent on the time of diagnosis, the start of medication, and the level of serum creatinine.<ref name="pmid24657897">{{cite journal| author=Moroni G, Ponticelli C| title=Rapidly progressive crescentic glomerulonephritis: Early treatment is a must. | journal=Autoimmun Rev | year= 2014 | volume= 13 | issue= 7 | pages= 723-9 | pmid=24657897 | doi=10.1016/j.autrev.2014.02.007 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24657897  }}</ref>
In the past the prognosis of Goodpasture syndrome was fatal.<ref name="pmid12597309">{{cite journal| author=Shah MK, Hugghins SY| title=Characteristics and outcomes of patients with Goodpasture's syndrome. | journal=South Med J | year= 2002 | volume= 95 | issue= 12 | pages= 1411-8 | pmid=12597309 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12597309  }}</ref> Today, the prognosis of Goodpasture syndrome is heavily dependent on the time of diagnosis, the start of medication, and the level of serum creatinine.<ref name="pmid24657897">{{cite journal| author=Moroni G, Ponticelli C| title=Rapidly progressive crescentic glomerulonephritis: Early treatment is a must. | journal=Autoimmun Rev | year= 2014 | volume= 13 | issue= 7 | pages= 723-9 | pmid=24657897 | doi=10.1016/j.autrev.2014.02.007 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24657897  }}</ref>



Revision as of 02:48, 25 April 2018

Goodpasture syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Goodpasture syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Goodpasture syndrome natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Goodpasture syndrome natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Goodpasture syndrome natural history, complications and prognosis

CDC on Goodpasture syndrome natural history, complications and prognosis

Goodpasture syndrome natural history, complications and prognosis in the news

Blogs on Goodpasture syndrome natural history, complications and prognosis

Directions to Hospitals Treating Goodpasture syndrome

Risk calculators and risk factors for Goodpasture syndrome natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2]Associate Editor(s)-in-Chief: Krzysztof Wierzbicki M.D. [3]

Overview

If left untreated, Goodpasture syndrome can progress to end stage renal disease and pulmonary failure. Complications of Goodpasture syndrome include, infections, alveolar hemorrhage, end stage renal disease, and pulmonary failure. The prognosis of Goodpasture syndrome is variable, as it depends upon the diagnosis, start of treatment and the level of serum creatinine.

Natural History

If left untreated, Goodpasture syndrome can progress to end stage renal disease and pulmonary failure.

Complications

Possible complications of Goodpasture syndrome include:

  • Infections with P. jiroveci[1]
  • Alveolar hemorrhage[2]
  • End stage renal disease
  • Pulmonary failure

Prognosis

  • Prognosis is generally good for patients with Goodpasture syndrome who receive treatment.
  • The 5 survival rate of patients with Goodpasture syndrome who receive treatment is approximately 80%.
  • Recent advances in pharmacotherapy and use of immunosuppressive and plasmapheresis have further improved the outcome of patients with Goodpasture syndrome.

In the past the prognosis of Goodpasture syndrome was fatal.[3] Today, the prognosis of Goodpasture syndrome is heavily dependent on the time of diagnosis, the start of medication, and the level of serum creatinine.[4]

The following are favorable prognostic factors:

  • Aggressive treatment with corticosteroids, plasmapheresis, and immunosuppressants.
  • Serum creatinine of less than 5.7 mg/dL

The following are poor prognostic factors:

  • Serum creatinine that is greater than 5.7 mg/dL
  • Patients who require long term dialysis
  • Glomerular Filtration Rate (GFR) of less than 15 mL/min
  • Advanced age
  • Low hemoglobin
  • High white blood cell count
  • Crescent formation that have extended greater than 80% of glomeruli
  • ANCA and anti-GBM antibodies present together [5]

The current 5 year survival rate of Goodpasture syndrome is greater than 80% and patients requiring long-term renal dialysis less than 30% in advent to earlier diagnosis and aggressive treatment regimen. [6]

References

  1. Greco A, Rizzo MI, De Virgilio A, Gallo A, Fusconi M, Pagliuca G; et al. (2015). "Goodpasture's syndrome: a clinical update". Autoimmun Rev. 14 (3): 246–53. doi:10.1016/j.autrev.2014.11.006. PMID 25462583.
  2. Panjwani AH, Deoskar RB, Falleiro J, Rajan KE (2003). "Goodpasture's Syndrome". Med J Armed Forces India. 59 (1): 77–9. doi:10.1016/S0377-1237(03)80119-3. PMC 4925784. PMID 27407468.
  3. Shah MK, Hugghins SY (2002). "Characteristics and outcomes of patients with Goodpasture's syndrome". South Med J. 95 (12): 1411–8. PMID 12597309.
  4. Moroni G, Ponticelli C (2014). "Rapidly progressive crescentic glomerulonephritis: Early treatment is a must". Autoimmun Rev. 13 (7): 723–9. doi:10.1016/j.autrev.2014.02.007. PMID 24657897.
  5. Levy JB, Hammad T, Coulthart A, Dougan T, Pusey CD (2004). "Clinical features and outcome of patients with both ANCA and anti-GBM antibodies". Kidney Int. 66 (4): 1535–40. doi:10.1111/j.1523-1755.2004.00917.x. PMID 15458448.
  6. Fernandes R, Freitas S, Cunha P, Alves G, Cotter J (2016). "Goodpasture's syndrome with absence of circulating anti-glomerular basement membrane antibodies: a case report". J Med Case Rep. 10 ( ): 205. doi:10.1186/s13256-016-0984-6. PMC 4962374. PMID 27459964.

Template:WH Template:WS